GUANZE MEDICAL (02427) issues profit warning, expecting a net loss attributed to shareholders of approximately 28 to 30 million RMB for the year 2025, compared to a profit in the previous year.

GUANZE MEDICAL (02427) announced that it is expected to incur a net loss attributable to owners of the company of RMB 28-30 million for the 12 months ending December 31, 2025, compared to a net profit of approximately RMB 17.2 million for the 12 months ending December 31, 2024. The expected loss for this period is mainly due to the combined effects of the following factors: the average selling price and quantity of imaging film products in 2025 are lower than the same period in 2024; sales revenue is expected to decrease from approximately RMB 155.7 million in 2024 to around RMB 88.4 million in 2025; and possible impairment of properties, factories, and equipment in 2025.